부산대학교 도서관

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.fertnstert.2009.03.081 Byline: David R. Meldrum (a), R. Jeffrey Chang (b), Dominique de Ziegler (c), William B. Schoolcraft (d), Richard T. Scott (e), Antonio Pellicer (f) Abstract: Several drugs, shown to be safe for other uses, have proven to be highly effective adjuncts for ovarian stimulation. The authors evaluate these "orphan" indications and make recommendations so that more patients will benefit from their use. Author Affiliation: (a) Reproductive Partners Medical Group, Redondo Beach, California (b) Department of Reproductive Endocrinology and Infertility, University of California, San Diego, San Diego, California (c) Universite Paris Descartes, Service de Gynecologie Obstetrique II et Medecine de la Reproduction, CHU Cochin Saint Vincent de Paul, Paris, France (d) Colorado Center for Reproductive Medicine, Englewood, Colorado (e) Reproductive Medicine Associates of New Jersey, Morristown, New Jersey (f) Instituto Valenciano de Infertilidad, University of Valencia, Valencia, Spain Article History: Received 8 September 2008; Revised 12 March 2009; Accepted 20 March 2009 Article Note: (footnote) D.R.M. has nothing to disclose. R.J.C. has performed consulting for Beckman-Coulter. D. de Z. holds stock in Ultrast, serves on the advisory board for Ferring, and has performed consulting for IBSA Pharmaceuticals. W.B.S. has nothing to disclose. R.T.S. has received research grants from EMD Serono, Organon, and Ferring. A.P. has nothing to disclose.